Abstract
<h2>Summary</h2> The field of structural DNA nanotechnology applies the programmability of Watson-Crick base pairing to the construction of custom nanostructures that are prescribed by the sequence information encoded in DNA molecules. Precisely defined geometries, highly programmable molecular interactions, and outstanding biocompatibility make DNA nanostructures a new category of nanocarriers for drug delivery. Over the past decade, the potential of using DNA nanocarrier-based formulation for cancer therapy has been extensively explored with the successful implementation of various therapeutic strategies, both <i>in vitro</i> and <i>in vivo</i>. Moreover, DNA nanocarriers can be encoded with complex instructions via sequence design, enabling therapeutic functions to be executed in a programmed, automatic manner. In this review, we summarize recent advances and discuss the challenges and opportunities in designer DNA nanostructure-enabled therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
